content_image/946670.jpg content_image/946671.jpg content_image/946669.jpg content_image/946672.jpg
OSC size capsules (Capsugelfi, Warner-Lambert), which were then closed. Four Beagle dogs were dosed orally with the capsules which provided 10 mg of Compound A per kg of body weight (mpk) followed by 5 mL/kg of water. The dogs were pre-acidified with a subcutaneous injection of pentagastrin about 10 to 15 minutes prior to dosing the capsules. The dose of pentagastrin was variable due to adverse reactions in the dogs, but each dog received enough pentagastrin to lower the stomach pH. The same dogs were also dosed orally with a control capsule. 

[0422] The same dogs (without pre-acidification) were also orally dosed with 10 mpk of (i) Compound A dissolved in propylene glycol-HCl-ethanol (98:2:5) and (ii) Com› pound A in an encapsulated polyethylene glycol-HCl gel. For each dosing run, blood samples were drawn from catheters placed in the cephalic vein at pre-dose at 0, 0.333, 0.5, 0.67, 1, 2, 4, 6, 8 and 24 hours after dosing. The sample extracts were extracted via a liquid-liquid extraction proce› dure employing methyl t-butyl ether to isolate Compound A from the biological mixture/plasma. Indinavir was used as the internal standard. The sample extracts were analyzed by LC/MS/MS in the positive ion mode using an electrospray interface. The area under the curve (AUC) was calculated by linear trapezoidal rule from observed data points using Microsoft Excel 97 SR-2. Arithmetic mean and standard error of the mean (SEM) for AUC, observed maximum plasma concentration (Cmax), and time of Cmax (Tmax) were calculated with Microsoft Excel v 97 SR-2. The results are shown in Tables 2, 3 and 4 below. 

<img src='content_image/946670.jpg'>

[0423] 

<img src='content_image/946671.jpg'>

[0424] 

<img src='content_image/946669.jpg'>

[0425] Tables 2-4 show that the Compound A-resin com› plex with pre-acidification has a pharmacokinetic profile similar to that of the glycol solution and the polyglycol gel capsule. An advantage of the resin complex over the solution and the gel formulations is that it is a solid which can facilitate handling and administration. Another advantage is that the resin complex is more stable thermally. Thermal stability studies conducted at 25° C. and 40° C. on these three formulations have indicated that the Compound A-resin complex has little or no growth of degradates (e.g., lactones) relative to the solution and gel formulations. The resin complex does require an acidic stomach in order to release the drug, but this can routinely and easily be accom› plished by administering the complex to the subject after a meal or with a carbonated beverage. 

[0426] While the foregoing specification teaches the prin› ciples of the present invention, with examples provided for the purpose of illustration, the practice of the invention encompasses all of the usual variations, adaptations and/or modifications that come within the scope of the following claims. 

What is claimed is: 

1. A pharmaceutical composition which comprises a cat› ion exchange resin complexed with a compound of Formula (I) or a pharmaceutically acceptable salt thereof: 

<img src='content_image/946672.jpg'>

wherein 

R 1 is C$_{1 }$-C$_{6 }$ alkyl, C$_{2}$-C$_{6 }$ alkenyl, C$_{2}$ -C$_{6 }$ alkynyl, C$_{3}$ -C$_{6 }$ cycloalkyl, aryl, substituted aryl, heteroaryl, or substi› tuted heteroaryl; wherein 

(i) each of the substituents on substituted aryl is inde› pendently 

(a) halogen, 

(b) cyano, 

(I) 

